title: [From orthoclone to denosumab, the fast growing market of monoclonal antibodies].
abstract: Monoclonal antibodies are a specific medicinal category within the current therapeutic armamentarium. Their market share is growing fast as they are often the only therapeutic option at some stages of certain diseases, due to their targeted action in the body and to an acceptable tolerance. The budget impact of monoclonal antibodies is increasing, leading payers and health authorities to growing attention and pressure when they have to decide on the reimbursement, coverage and pricing of these products. The launch of biosimilars after patent expiry of some of these drugs will take time in view of the complexity of these molecules, and is not likely to significantly impact the cost of these therapies.
authors.affiliation: JNB Développement, 6 rue du Général de Larminat, 75015 Paris, France. jnbiot@jnbd.com
authors.forename: Jacques
authors.initials: J
authors.lastname: Biot
authors.forename: Christelle
authors.initials: C
authors.lastname: Fasano
authors.forename: Céline
authors.initials: C
authors.lastname: Dos Santos
mesh_terms: D000911:Antibodies, Monoclonal / Q000191:economics* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D002017:Budgets; D000069448:Denosumab; D016527:Drug Costs; D004345:Drug Industry / Q000191:economics / Q000331:legislation & jurisprudence; D004363:Drug Utilization / Q000191:economics / Q000706:statistics & numerical data; D005060:Europe; D019981:Health Care Sector / Q000639:trends*; D006801:Humans; D007349:Insurance, Health, Reimbursement; D016853:Muromonab-CD3 / Q000191:economics; D010330:Patents as Topic; D053245:RANK Ligand / Q000191:economics; D014481:United States
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D016853:Muromonab-CD3; D053245:RANK Ligand; D000069448:Denosumab